Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587
about
2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcri[2',5'-Bis-O-(tert-butyldimethylsilyl)]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) derivatives of purine and pyrimidinenucleosides as potent and selective inhibitors of human immunodeficiency virus type 1Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitroAction of uracil analogs on human immunodeficiency virus type 1 and its reverse transcriptaseAnalysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptaseSpecific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitorsHuman immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analoPatterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor lovirideMolecular docking of (5E)-3-(2-aminoethyl)-5-(2- thienylmethylene)-1, 3-thiazolidine-2, 4-dione on HIV-1 reverse transcriptase: novel drug acting on enzyme.A validated new method for nevirapine quantitation in human plasma via high-performance liquid chromatography.High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.Inhibition of HIV-1 reverse transcriptase and virus replication by a non-nucleoside dipyridodiazepinone BI-RG-587 (Nevirapine).Antiretroviral therapy: reverse transcriptase inhibition.Antiviral therapy for human immunodeficiency virus infectionsPharmacokinetics of nevirapine: initial single-rising-dose study in humans.Clinical utility of current NNRTIs and perspectives of new agents in this class under development.Antiviral therapy: current concepts and practicesTreatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.Synthesis, biological evaluation and molecular modeling studies of N-aryl-2-arylthioacetamides as non-nucleoside HIV-1 reverse transcriptase inhibitors.Nitroimidazoles Part 6. Synthesis, structure and in vitro anti-HIV activity of new 5-substituted piperazinyl-4-nitroimidazole derivatives.Arylthiopyrrole (AThP) derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis, structure-activity relationships, and docking studies (part 2).Arylthiopyrrole (AThP) derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis, structure-activity relationships, and docking studies (part 1).HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase.Imidazo[1,5-b]pyridazine-d4T conjugates: synthesis and anti-human immunodeficiency virus evaluation.Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.What can be Expected from Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections?4D-QSAR study of HEPT derivatives by electron conformational-genetic algorithm method.Conformation depends on 4D-QSAR analysis using EC-GA method: pharmacophore identification and bioactivity prediction of TIBOs as non-nucleoside reverse transcriptase inhibitors.Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase.Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GSAnti-HIV, antimycobacterial and antimicrobial studies of newly synthesized 1,2,4-triazole clubbed benzothiazolesDevelopment and Validation of a Rapid Liquid Chromatography Tandem Mass Spectrometry Method to Quantify Nevirapine in Human Plasma and its Application to Bioequivalence Study in Healthy Human Subjects
P2860
Q28316183-FCB09AFB-580B-46D0-8CC6-B8BD6EAD6A61Q28318473-0498AF77-44CF-41A6-9031-5B4BD77C7EBCQ28367552-14A917C7-C1F6-4B8B-BE36-ED2BFCF8D14EQ28367677-FC1F3AD3-8FAA-457D-9705-7F476C8B5934Q28368003-902D928A-7955-41D8-830B-8500C140D27AQ28368032-E73DC138-5265-41AE-B687-A02FBA70A6BCQ28368045-29824840-0CC8-404D-A6DA-A5DA18AEF79BQ28369293-02A7B9FA-F103-49F0-B609-6327A8DFB1CDQ30422172-D6800379-A347-4C8B-873B-327D8AC53FB9Q33215941-2C2D756E-2FE0-47FB-81FF-8DBF73CAA6EFQ33796791-C7CC8FE1-38EE-46E1-AE43-DD81CAB54BADQ33850152-3EB73E43-5748-4898-AD2B-DDEC6F67F09CQ35310043-AE1BC8FB-A434-4E89-9C73-2F69CD4D5E34Q35322871-3BBFF3ED-F7B1-4B38-A39F-3285813A93B4Q35366050-16D6C42E-D9B7-456A-91F8-9A0A4B38DC41Q35808226-C997CDFA-0BE7-4C8E-A6CA-48412C8AEC4DQ35842270-749A20E5-499F-4C38-9D4F-3634D0D7A3D6Q36070394-8F2128FB-39D7-466F-B356-E2AFE85EFB60Q36651931-5F5782A0-9AC0-4767-AC15-7E7EB83F46DDQ39664373-B462FC87-8D13-4FA6-A226-BF6288493A38Q40073996-82084237-FB8D-4C84-AADC-C5E094AFDAA1Q40211081-A385AD58-7374-42E0-898B-A0B24C3D89E8Q40211088-0F70DC25-F671-4CAF-8C68-4D59DCD5C6EDQ40486578-61B92EC4-8ECD-412F-AD80-2C0A0F417B54Q40983879-B3E3616B-27D0-45F3-97B0-05314127A2FDQ44195803-D0544C4F-4FCF-4578-AE64-644B88388CB4Q45748524-FA9F1666-F307-4124-8AEE-6618BFB9CEB2Q47977270-8BF81B20-7B82-4F3D-B3AF-B836459A19DFQ51367473-B2947C00-2D6B-4902-A973-881C86CFDB2AQ52845326-FE294D49-DDE5-4518-B62A-2990B766E205Q57133963-B548421A-5CE1-43D8-8F34-D0546167A009Q57269190-7849381D-7331-4D63-9915-31D88717F27DQ58307180-0FD486B2-5923-4D00-9E67-191F7278C2B5
P2860
Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587
description
1991 nî lūn-bûn
@nan
1991 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Inhibition of human immunodefi ...... dipyridodiazepinone BI-RG-587
@ast
Inhibition of human immunodefi ...... dipyridodiazepinone BI-RG-587
@en
Inhibition of human immunodefi ...... dipyridodiazepinone BI-RG-587
@nl
type
label
Inhibition of human immunodefi ...... dipyridodiazepinone BI-RG-587
@ast
Inhibition of human immunodefi ...... dipyridodiazepinone BI-RG-587
@en
Inhibition of human immunodefi ...... dipyridodiazepinone BI-RG-587
@nl
prefLabel
Inhibition of human immunodefi ...... dipyridodiazepinone BI-RG-587
@ast
Inhibition of human immunodefi ...... dipyridodiazepinone BI-RG-587
@en
Inhibition of human immunodefi ...... dipyridodiazepinone BI-RG-587
@nl
P2093
P356
P1476
Inhibition of human immunodefi ...... dipyridodiazepinone BI-RG-587
@en
P2093
J L Sullivan
K D Hargrave
K Grozinger
R J Eckner
V J Merluzzi
P304
P356
10.1093/INFDIS/163.5.966
P407
P577
1991-05-01T00:00:00Z